drugset
drugset / Trial / NCT00187057

Study for Treatment of Cancer in Children With Ataxia-telangiectasia

NCT00187057 ↗

Completed 6 enrolled St. Jude Children's Research Hospital Children's Hospital of Philadelphia · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a pilot/feasibility study designed to investigate the feasibility of treating children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as non-A-T patients with cancer would receive.

Timeline

Start
2002-09
Primary completion
2006-08
Completion
2013-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 1 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Subject Cytarabine Small molecule 100 mg/m2 Intravenous
Subject Cytarabine Small molecule 300 mg/m2 Intravenous
Subject Daunorubicin Small molecule 20 mg/m2 Intravenous
Subject Daunorubicin Small molecule 25 mg/m2 Intravenous
Subject Daunorubicin Small molecule 30 mg/m2 Intravenous
Subject Daunorubicin Small molecule 50 mg/m2 Intravenous
Subject Dexamethasone Small molecule 6 mg/m2 Oral
Subject Dexamethasone Small molecule 8 mg/m2 Oral
Subject Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Subject Etoposide Small molecule 225 mg/m2 Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule 75 mg/m2 Oral
Subject Methotrexate Small molecule 2 mg/m2 Intramuscular
Subject Methotrexate Small molecule 3 mg/m2 Intramuscular
Subject Methotrexate Small molecule 20 mg/m2 Intramuscular
Subject Methotrexate Small molecule 40 mg/m2 Intramuscular
Subject Methotrexate Small molecule 2000 mg/m2 Intramuscular
Subject Prednisone Other / unclassified 40 mg/m2 Oral
Subject Prednisone Other / unclassified 60 mg/m2 Oral
Subject Vinblastine Small molecule 6 mg/m2 Intravenous
Subject Vincristine Small molecule 1 mg/m2 Intravenous
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous
Subject Vincristine Small molecule 2 mg/m2 Intravenous
Subject asparaginase Protein / enzyme biologic 10000 iu Intramuscular
Subject procarbazine Small molecule 100 mg/m2 Oral

Indications

ataxia telangiectasia